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With the assistance of proteins called
chaperones, newly translated proteins fold
into the three-dimensional shapes that are
critical to their function. When proteins
fold abnormally or become unstable, the
consequences can be dire for cells, partic-
ularly neurons, which are exquisitely
sensitive to the accumulation of misfolded
proteins. Many neurodegenerative diseas-
es, like Parkinson’s and Creutzfeldt–Jakob,
are associated with an accumulation of
misfolded proteins. Huntington’s disease
(HD), an incurable condition that causes
progressive loss of neurological function, is
one of several hereditary neurodegenera-
tive diseases known as poly-glutamine
(polyQ) diseases that result from expan-
sions of CAG (the trinucleotide repeat that
codes for glutamine) in the protein-coding
region of a gene (in HD, the gene is
huntingtin). Proteins with these abnormally
long tracts of glutamines are highly
susceptible to misfolding and aggregation.
Although it was first thought that aggre-
gates of polyQ proteins caused neurotox-
icity in polyQ diseases, recent studies have
suggested that in fact the soluble misfolded
protein precursors are the neurotoxins.
Based on increasing evidence that mis-
folded proteins are the culprit in many
neurogenerative diseases, Daniel Neef,
Michelle Turski, and Dennis Thiele (this
issue of PLoS Biology) reasoned that thera-
pies targeting proteins that regulate folding
may prove promising.
There are currently no cures for any of
the polyQ diseases, but researchers hy-
pothesize that if the abnormal polyQ
proteins could be stabilized into their
correct conformation, the neurotoxicity
associated with protein misfolding in
neuronal tissues might be prevented,
leading to arrest of the disease process.
Previous studies in cell culture and animal
models of neurodegenerative disease
found that increasing the amount of
available protein chaperones, such as
Hsp70 and Hsp40, can suppress protein
aggregation and prevent polyQ disease–
related damage to neurons.
Heat Shock Transcription Factor 1
(HSF1) is a ‘‘master regulator’’ of the
protein chaperone response. HSF1 is
inactive most of the time. But under
conditions that are likely to put stress on
proteins and cause them to misfold—such
as preexisting misfolded proteins, oxida-
tion, or heat—HSF1 is activated and
directs the production of multiple protein
chaperones. In neurons, HSF1 does not
appear to be very efficiently converted to
its active form, making these cells partic-
ularly likely to accumulate large amounts
of misfolded proteins, and thus more
susceptible to damage than other cell
types.
Because of its role as a master regulator
of the protein stress response, HSF1
activation is an attractive target for
researchers looking for new therapies to
treat diseases associated with protein
misfolding. Although previous screens
identified compounds that activate HSF1,
they often did so in ways that were
ultimately detrimental to cells, such as by
causing increased amounts of misfolded
proteins to accumulate, or by inhibiting
Hsp90, a protein chaperone that has
critical roles in cell growth, signaling,
and proliferation. Thus, when Neef,
Turski, and Thiele set out to identify small
molecules that would activate human
HSF1 from a library of over 10,000
compounds, they designed their screen to
be insensitive to compounds that promot-
ed proteotoxicity or inhibited Hsp90. The
screen used a strain of the yeast Saccharo-
myces cerevisiae that had been engineered to
express human HSF1 and would grow
only when this introduced protein was
activated by the presence of a successful
candidate compound. Using this screen,
the researchers were able to quickly
identify 33 compounds that allowed acti-
vated HSF1-dependent yeast growth to
occur. They then focused on the com-
pound (which they called HSF1A) that
caused the most robust HSF1-dependent
yeast growth.
To find out if HSF1A could initiate an
HSF1 response in mammalian neurons,
the researchers added it to an in vitro
culture of rat neuronal precursor cells that
expressed a mutant human huntingtin gene
containing an expanded tract of gluta-
mines. Hsp70 expression was increased in
these cells, and less misfolded huntingtin
protein accumulated, compared to cells to
which HSF1A was not added.
Turning next to an in vivo animal
model, the researchers employed fruit flies
that expressed a mutant form of human
MJD/SCA3 gene (associated with the
polyQ disease Machado-Joseph). In the
experimental system, expression of this
gene was limited to the fruit flies’ eyes,
where accumulation of the mutant protein
caused loss of pigmentation and smaller
eyes. When these flies were fed HSF1A,
their progeny had eyes that looked similar
to wild-type flies, indicating that HSF1A
was partially suppressing the cell toxicity
caused by polyQ protein accumulation.
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Fruit flies expressing a mutant form of
the misfolded human MJD protein (mid-
dle) exhibit abnormal eye pigmentation
and eye size. Feeding the flies HSF1A
(right) causes the eye to resemble wild-
type eyes (left).
doi:10.1371/journal.pbio.1000290.g001
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mine how HSF1A was causing activation
of HSF1, the researchers confirmed that
HSF1A was not acting to increase protein
misfolding and it was not inhibiting
Hsp90. Instead, they found that HSF1A
was interacting with the TRiC/CCT
cytosolic chaperone complex, which helps
to fold cytoskeletal proteins like tubulin
and actin. Although TriC activity was not
previously known to have a role in HSF1
activity, a recent study found that it
inhibits polyQ protein aggregation and
cytotoxicity in yeast and animal cells.
Thus, HSF1A may be suppressing protein
misfolding and aggregation by positively
regulating TRiC activity.
Although HSF1A—as well as other
activators of HSF1 that may be iden-
tified in the future by Neef, Turski, and
Thiele’s humanized yeast high-throughput
screen—have potential for treating pro-
tein misfolding diseases such as HD or
Parkinson’s, the researchers caution that
several questions still need to be an-
swered. For example, how is HSF1A
interacting with the TriC complex, and
how might this affect HSF1 activation?
And, what negative effects on cell meta-
bolic processes might arise from thera-
peutic activation of the protein chaperone
response? Studies are currently under way
to address these issues and further explore
HSF1’s potential as a therapeutic target in
protein misfolding–related neurodegener-
ative diseases.
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